𝔖 Bobbio Scriptorium
✦   LIBER   ✦

VP16-213 in combined modality treatment of small cell carcinoma of the lung

✍ Scribed by Newman, Steven B.; Bitran, Jacob D.; Golomb, Harvey M.; Hoffman, Philip C.; DeMeester, Tom R.; Raghavan, Vathsala

Book ID
122369905
Publisher
Elsevier Science
Year
1982
Weight
411 KB
Volume
18
Category
Article
ISSN
0277-5379

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Doxorubicin, cyclophosphamide and VP16-2
Doxorubicin, cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer
✍ Joseph Aisner; Margaret Whitacre; David A. VanEcho; Margaret Wesley; Peter H. Wi πŸ“‚ Article πŸ“… 1982 πŸ› Springer 🌐 English βš– 742 KB

Small cell lung cancer requires aggressive combination chemotherapy. The three active agents, doxorubicin (A) 45 mg/m2 i.v. day 1, cyclophosphamide (C) 1.0 mg/m2 i.v. day 1 and VP16-213 (E) 50 mg/m2/day i.v. days 1-5 were given together. The combination (ACE) was given every 21 days without chest ir

Vincristine, adriamycin, cyclophosphamid
Vincristine, adriamycin, cyclophosphamide, and etoposide (VP16-213) in small-cell anaplastic carcinoma of the lung
✍ F. E. Eyben; Γ…. Arwidi; C. Hellekant; K. Jonsson; S. Γ…. Lindahl; W. Mattsson; L. πŸ“‚ Article πŸ“… 1982 πŸ› Springer 🌐 English βš– 299 KB

Twelve patients with small-cell anaplastic carcinoma of the lung were treated with vincristine 1 mg/m2 i.v. day 1, adriamycin 50 mg/M2 i.v. day 1, cyclophosphamide 1,000 mg/m2 i.v. day 1, and etoposide 80 mg/m2 i.v. day 2, 4, 6 given on an outpatient basis and repeated at 3-week intervals. As consol

Epipodophyllotoxin (VP16-213) in small c
Epipodophyllotoxin (VP16-213) in small cell carcinoma of the bronchus resistant to initial combination chemotherapy
✍ P. G. Harper; M. B. Dally; D. M. Geddes; S. G. Spiro; J. F. Smyth; R. L. Souhami πŸ“‚ Article πŸ“… 1982 πŸ› Springer 🌐 English βš– 168 KB

Thirty-eight patients with small cell carcinoma of the bronchus resistant to initial chemotherapy with cyclophosphamide methotrexate and CCNU, were treated with VP16-213 alone in a dose of 120 mg/m2 i.v. on days 1, 3, and 5 every 3 weeks. Twelve patients died before three courses of treatment. In 26